Drug Approval | August 27, 2022
Lupin receives UK MHRA Approval of Lutio for treatment of COPD
Lutio has the potential to offer significant cost savings when available to UK patients.
Lutio has the potential to offer significant cost savings when available to UK patients.
This Bioforum will provide the latest insights on delivering increased speed, greater flexibility and enhanced quality while reducing the cost, and risks of navigating the evolving biopharma landscape
The initiative aims to reach out to more than 20 million people across the country and a number of social media influencers have also pledged to extend their whole-hearted support for the noble cause
The citizens of Oman will soon have a coordination center that will provide end to end services for healthcare facilities of Jaslok.
This rapid analytical technique provides additional information about the polymorph and solid-state properties of active pharmaceutical ingredients (APIs)
DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
OrderPoint was designed as an advanced DTR solution from its first release in 2016.
Genentech will be granted an exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs.
GlobalData’s ‘Pharmaceutical Intelligence Center’ observes that India is still in the nascent stage of developing these potential therapies as currently only four cell/gene therapy molecules are being developed in the country.
Subscribe To Our Newsletter & Stay Updated
